Drug-Drug Interactions in HIV/HCV Coinfection

Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.

HCV Racial Disparities and Treatment Outcomes

Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients.

Preventing HCV With Needle/Syringe Programs

Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject ...

Short-Duration Treatment Regimens for HCV

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved ...

Treatment Challenges for Genotype 3 HCV

Data have shown patients with genotype 3 HCV have faster progression of fibrosis and higher rates of cirrhosis, severe steatosis, and hepatocellular carcinoma.

Hepatocellular Carcinoma: Treatment Challenges

Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are ...

Hepatitis B: Current State of Affairs

One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access ...

Latest News

Tenofovir Disoproxil Fumarate Approved for Use in Younger Patients With HBV

Tenofovir Disoproxil Fumarate Approved for Use in Younger Patients With HBV

The Indication section has been revised to state that Viread is intended for use in the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg.

Survival Similar With Donor Hearts From Donors With Hepatitis C

Survival Similar With Donor Hearts From Donors With Hepatitis C

Transplant patients with hearts from donors with HCV infection and obese donors have similar survival rates as patients with other donor hearts.

Updated Recommendations, Hepatitis A Vaccine Postexposure Prophylaxis and Travel

Updated Recommendations, Hepatitis A Vaccine Postexposure Prophylaxis and Travel

The Advisory Committee on Immunization Practices Hepatitis Vaccines Work Group has updated recommendations for hepatitis A vaccination for PEP and PrEP.

HCV Reinfection Rates Examined Following Successful Treatment

HCV Reinfection Rates Examined Following Successful Treatment

In order to determine HCV reinfection rates following sustained virologic response (SVR) in the overall population as well as in PWID, the study authors analyzed data obtained from a population-based study that included >1.7 million people that were tested for HCV.

Real-World Data Show Rising HCV Epidemic Among Young Adults

Real-World Data Show Rising HCV Epidemic Among Young Adults

The study included 17,149,480 patients obtained from 2 national laboratory datasets who were screened between 2013 and 2016 based on an AB test.

HCV Treatment Linked to Reduced Risk of Incident CVD Events

HCV Treatment Linked to Reduced Risk of Incident CVD Events

ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.

Chronic Hepatitis C Infection and Parkinsonism: What's the Link?

Chronic Hepatitis C Infection and Parkinsonism: What's the Link?

In order to determine the association between CHC and parkinsonism, the study authors utilized the National Health Insurance Research Database in Taiwan to identify CHC patients between 2004 and 2012.

Hepatocellular Carcinoma Risk Following Antiviral Therapy for HCV Examined

Hepatocellular Carcinoma Risk Following Antiviral Therapy for HCV Examined

The retrospective study aimed to determine the risk of incident, or de novo, HCC following different regimens of antiviral therapy.

Does Obesity Impact Virological Response in HCV Patients on DAA Therapy?

Does Obesity Impact Virological Response in HCV Patients on DAA Therapy?

The review analyzed 168 patients treated with an oral DAA at a single center from 2015 to 2017.

Direct-Acting Antiviral Therapy Uptake Examined Among HCV Patients

Direct-Acting Antiviral Therapy Uptake Examined Among HCV Patients

The study utilized data from the Chronic Hepatitis Cohort Study, an observational cohort study, to assess demographic and clinical characteristics associated with DAA use.

Sign Up for Free e-newsletters